Raphi Levy, Chief Financial Officer of Alpha Tau Medical Ltd. (NASDAQ:DRTS), filed a Form 4 on August 12, 2026, disclosing transactions in ordinary shares dated August 11, 2026, made pursuant to a Rule 10b5-1 plan.

Key Highlights

  • Role: Raphi Levy is identified as Chief Financial Officer of Alpha Tau Medical Ltd.
  • Exercise transaction: Levy acquired 17,730 ordinary shares on 08/11/2026 via an M-coded transaction at a price of $2.98 per share.
  • Sale transaction: Levy disposed of 17,730 ordinary shares on 08/11/2026 via an S-coded transaction at a price of $14.0032 per share.
  • Post-transaction ownership: Following the exercise, Levy held 107,910 ordinary shares directly; following the sale, beneficial ownership stood at 90,180 ordinary shares directly.
  • Rule 10b5-1 plan: The filing indicates the transactions were made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Alpha Tau Medical CFO Transaction Details: Exercise and Sale of Ordinary Shares

According to the Form 4 filed with the SEC on August 12, 2026, Raphi Levy, Chief Financial Officer of Alpha Tau Medical Ltd. (NASDAQ:DRTS), reported two transactions in the company's ordinary shares, both dated August 11, 2026. The filing indicates both transactions carried a deemed execution date of 08/11/2026. The form was filed by one reporting person.

The first transaction, coded "M," reflects the acquisition of 17,730 ordinary shares at a price of $2.98 per share, bringing Levy's directly held beneficial ownership to 107,910 ordinary shares at that point. The second transaction, coded "S," reflects the disposition of 17,730 ordinary shares at a price of $14.0032 per share, reducing Levy's direct beneficial ownership to 90,180 ordinary shares following the reported transactions. Both ownership positions are listed as held directly.

The filing notes a checkbox indicating that the transactions were made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). No derivative securities transactions were reported in Table II of the filing. The filing was signed by Raphi Levy on August 12, 2026.

What Was Disclosed

The Form 4 discloses that Alpha Tau Medical's CFO, Raphi Levy, exercised and sold 17,730 ordinary shares on August 11, 2026, under a Rule 10b5-1 plan, with resulting direct beneficial ownership of 90,180 ordinary shares.